5-amino-2-hydroxybenzoic acid

C1=CC(=C(C=C1N)C(=O)O)O

InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

KBOPZPXVLCULAV-UHFFFAOYSA-N

5-Aminosalicylic acid; mesalamine; Mesalazine; 89-57-6; 5-Amino-2-hydroxybenzoic acid; Asacol; Pentasa; Canasa; 5-ASA; Claversal; Rowasa; Salofalk; m-Aminosalicylic acid; Lialda; Mesasal; Benzoic acid, 5-amino-2-hydroxy-; Fisalamine; Apriso; Lixacol; sfRowasa; p-Aminosalicylsaeure; Asacolitin; Mesalazina; Mesalazinum; Iialda; 5-amino-2-hydroxy-benzoic acid; Asacol HD; Mesalamine [USAN]; 5-Amino Salicylic Acid; SALICYLIC ACID, 5-AMINO-; 2-Hydroxy-5-aminobenzoic acid; MAX-002; 3-carboxy-4-hydroxyaniline; MFCD00007877; NSC 38877; NSC-38877; Mesalazine [INN]; MLS001424012; 4Q81I59GXC; CHEBI:6775; mesalamine (USAN); 5-?Aminosalicylic Acid (Mesalazine); CAS-89-57-6; NCGC00016344-03; Mesalazinum [Latin]; SMR000145728; DSSTox_CID_4506; DSSTox_RID_77435; DSSTox_GSID_24506; Mesalazina [Spanish]; p-Aminosalicylsaeure [German]; Mesavancol; Delzicol; Mesavance; Mezavant; Mesalazine MMX; Mezavant XL; Mesalamine (USP); Pentasa (TN); Salofalk Granu-Stix; Apriso (TN); Asacol (TN); Canasa (TN); Lialda (TN); Rowasa (TN); 5-AS; CCRIS 7334; SR-01000763486; Mesalamine [USAN:USP]; EINECS 201-919-1; BRN 2090421; UNII-4Q81I59GXC; AI3-15564; HSDB 7512; AJG-501; SPD 476; SPD-476; SPD-480; Mesalamine (TN); Delzicol (TN); Sfrowasa (TN); Mesalamine (Lialda); 5-aminosalicylic_acid; MD-0901; 5-Aminosalicyclic acid; 5-amino-salicylic acid; MESALAMINE [MI]; MESALAZINE [JAN]; Prestwick0_001069; Prestwick1_001069; Prestwick2_001069; Prestwick3_001069; MESALAMINE [HSDB]; WLN: ZR DQ CVQ; Z-206; MESALAMINE [VANDF]; CHEMBL704; Mesalazine (JP17/INN); EC 201-919-1; cid_4075; MESALAZINE [MART.]; MESALAMINE [USP-RS]; MESALAZINE [WHO-DD]; Oprea1_847633; SCHEMBL31297; 3amino-6-hydroxybenzoic acid; BSPBio_001058; KBioGR_002425; KBioSS_002431; 4-14-00-02058 (Beilstein Handbook Reference); MLS000758287; 5-Aminosalicylic acid, 95%; 5-Aminosalicylic acid, tablet; BIDD:GT0811; 3-amino-6-hydroxybenzoic acid; SPBio_002969; BPBio1_001164; GTPL2700; ZINC1688; 5-Amino 2-hydroxy benzoic acid; DTXSID5024506; MESALAMINE [ORANGE BOOK]; MESALAZINE [EP IMPURITY]; SCHEMBL18038934; 5-Aminosalicylic acid, >=99%; BDBM60918; KBio2_002425; KBio2_004993; KBio2_007561; KBio3_002904; MESALAZINE [EP MONOGRAPH]; cMAP_000045; HMS1571E20; HMS2051M21; HMS2090I09; HMS2098E20; HMS3393M21; HMS3649K15; HMS3651M15; HMS3715E20; MESALAMINE [USP MONOGRAPH]; Pharmakon1600-01505993; BCP05326; NSC38877; Tox21_110384; Tox21_201610; Tox21_303125; AC8101; BBL013046; NSC759301; s1681; STK301678; AKOS000118959; Tox21_110384_1; AC-2764; BCP9000175; CCG-100829; DB00244; HS-0100; NC00079; NSC-759301; NCGC00016344-01; NCGC00016344-02; NCGC00016344-04; NCGC00016344-05; NCGC00016344-07; NCGC00090934-01; NCGC00090934-02; NCGC00257142-01; NCGC00259159-01; 5-amino-2-hydroxobenzoic acid monohydrate; BP-13074; HY-15027; SY002854; 5-Aminosalicylic acid, analytical standard; A0317; AB00374979; AM20060091; FT-0619950; SW197303-4; EN300-18389; C07138; D00377; AB00374979-09; AB00374979-10; AB00374979_11; AB00374979_12; Q412479; 5-amino-2-hydroxybenzoic acid,5-Aminosalicylic acid; Q-201355; SR-01000763486-3; SR-01000763486-4; SR-01000763486-9; Z57127471; F1918-0003; Mesalazine, European Pharmacopoeia (EP) Reference Standard; Mesalamine, United States Pharmacopeia (USP) Reference Standard; Mesalamine, Pharmaceutical Secondary Standard; Certified Reference Material; Mesalazine for system suitability, European Pharmacopoeia (EP) Reference Standard; 51481-17-5